Overview

Ketamine for Treatment Resistant Late-Life Depression

Status:
Completed
Trial end date:
2020-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the effectiveness of a single infusion of ketamine (KET), to determine which dose is optimal 7 days after infusion using Bayesian Adaptive Randomization, and to learn about how ketamine works in the body and brain in persons with late-life treatment resistant depression.
Phase:
Phase 3
Details
Lead Sponsor:
VA Office of Research and Development
Treatments:
Ketamine
Midazolam